L'intérêt à découvert pour Under Armour donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Under Armour. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Under Armour (NYSE:UAA) Stock, Rapport sur les intérêts à découvert

Under Armour

Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and elsewhere. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996 and is led by controlling shareholder Kevin Plank.

Under Armour Inc

WIIM

SURG

SurgePays shares are trading higher after announcing an agreement with AT&T that enables the company to offer mobile wireless, voice, data, and messaging services.

SurgePays, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) shares are trading higher after the company inked a deal with AT&amp;T Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) to provide mobile wireless, voice, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42110967/surgepays-establishes-strategic-agreement-with-at-t" rel="noreferrer noopener">data, and messaging services</a>.
As per a multi-year mobile virtual network operator (MVNO) agreement, SurgePays will offer its customers reliable 4G LTE and 5G services using AT&amp;T&#8217;s wireless network, which covers over 99% of Americans in North America.
The AT&amp;T agreement enables SurgePays to empower other businesses to deliver MVNO wireless services while expanding into underserved and rural markets. Leveraging its vast network of convenience stores, bodegas, and neighborhood locations, SurgePays ensures easy access to prepaid wireless and financial products.
Brian Cox, Chairman and CEO, said, &#8220;Once service integration with AT&amp;T is complete, we will be able to provide services on a network that our customers can depend on to stay securely connected, whether they are existing SurgePays customers or new ones coming to us through our convenience store distribution channel, operation centers or online.&#8221;
&#8220;Back in July, we announced the hiring and appointment of&nbsp;Joseph Gomez&nbsp;as vice president of MVNO Operations,&#8221; added Cox. &#8220;Joe had served AT&amp;T for decades leading strategic initiatives, developing partnerships and overseeing national sales and distribution channels. He has wasted no time in following through on his charge of driving our MVNO strategy with a focus on market share growth.&#8221;
Price Action: SURG shares are up 17.1% at $1.71 at the last check Thursday.
Image sourced from Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42116183" target="_blank" rel="noreferrer noopener">Michael Saylor Predicted Bitcoin To Hit $13 Million — If It Happens, It Will Entail &#8216;Massive Hyperinflation,&#8217; Analyst Warns</a></li>
</ul>

Equities

News

Contracts

Small Cap

Movers

SurgePays Teams Up With AT&T For Affordable Wireless Solutions Nationwide; Stock Gains

At the <a href="https://cannabismarketspotlight.com/california/anaheim-november-12/">Cannabis Market Spotlight: California</a> event in Anaheim, Lisa Weser, founder and CEO of Trailblaze, addressed a core debate within the cannabis industry: balancing consumer-driven product trends with a commitment to quality production. 
Weser, alongside other industry professionals, shared insights on how cannabis brands can adapt to shifting consumer preferences while remaining true to high production standards.
<h3 class="wp-block-heading">Consumer Demand or Industry Direction?</h3>
Weser's panel tackled a foundational question: are consumer preferences driving changes in the cannabis industry, or is the industry itself setting expectations? Speaking with experts from Papa &amp; Barkley, Jetty Extracts, Natura, and Timeless Vapes, Weser observed that perspectives on this issue vary widely.
See Also: <a href="https://www.benzinga.com/news/events/24/11/42115223/tax-woes-hemp-rules-california-cannabis-authority-nicole-elliott">From Tax Woes To Hemp Rules: Department Of Cannabis Control&#8217;s Nicole Elliott Outlines Regulatory Goals</a>
One common theme in the discussion was the need to "meet consumers where they are," a concept familiar in the consumer goods space. This approach focuses on crafting products that appeal directly to consumers' tastes. 
"We're seeing new consumers, especially younger ones, drawn to products with bold flavors," Weser said, noting the appeal of flavor-centric offerings over traditional high-grade cannabis flowers for some segments of the market.
<h3 class="wp-block-heading">Back to Basics: Quality First</h3>
In contrast, other panelists argued for a renewed focus on quality in cannabis production. They expressed concern that while consumer trends are essential, some brands may have strayed too far from the core values of cultivating excellent cannabis. According to Weser, many industry leaders believe that true product quality "starts at the farm," emphasizing that the cannabis industry should prioritize strong cultivation practices rather than relying solely on novelty.
This quality-focused viewpoint suggests that long-term success may be achieved by building on reliable practices, producing products that satisfy discerning customers, and reinforcing brand integrity.
<h3 class="wp-block-heading">Striking a Balance</h3>
Weser highlighted that both approaches hold weight in today's diverse cannabis market. Flavor-driven products may help engage newer consumers while focusing on quality that resonates with established users. "Both approaches are valid in today's market," she remarked, underscoring the importance of accommodating the varied needs of cannabis consumers.
This dialogue reflects a larger conversation in the cannabis industry about balancing the drive to meet consumer preferences with a dedication to sustainable quality. By exploring these perspectives, Weser's panel provided valuable takeaways on how brands can connect with different customer bases while maintaining high standards.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111795/californias-cannabis-future-why-one-expert-believes-the-market-will-hold-strong" target="_blank" rel="noreferrer noopener">California's Cannabis Future: Why One Expert Believes The Market Will Hold Strong</a></li>
</ul>
Image: AI-Generated Image

Cannabis

Events

Exclusives

Interview

'Innovation Starts At The Farm': How Cannabis Brands Balance Quality With Consumer Demand

GE Vernova shares are trading higher after Wells Fargo initiated coverage on the stock with an Overweight rating and announced a $385 price target.

AMZN

Amazon shares are trading lower following a report suggesting the company is likely to be investigated under the EU's Digital Markets Act next year.

The Container Store shares are trading lower after the company announced it expects the conditions of the sales and purchase agreement (SPA) with Beyond Inc to remain unsatisfied.

Mizuho analyst Gregg Moskowitz maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $165 to $195.

Price Target

Analyst Ratings

SNOW

Mizuho Maintains Outperform on Snowflake, Raises Price Target to $195

Financial giants have made a conspicuous bullish move on EHang Holdings. Our analysis of options history for EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) revealed 48 unusual trades.
Delving into the details, we found 45% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 46 were puts, with a value of $8,928,901, and 2 were calls, valued at $137,000.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $7.0 to $16.0 for EHang Holdings over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in EHang Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to EHang Holdings's substantial trades, within a strike price spectrum from $7.0 to $16.0 over the preceding 30 days.
<h3>EHang Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732207214_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$16.00</td>
<td>$410.0K</td>
<td>1.7K</td>
<td>3.3K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$16.00</td>
<td>$410.0K</td>
<td>1.7K</td>
<td>1.3K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.2</td>
<td>$3.9</td>
<td>$3.96</td>
<td>$16.00</td>
<td>$376.8K</td>
<td>1.7K</td>
<td>5.3K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$16.00</td>
<td>$350.0K</td>
<td>17.8K</td>
<td>5.4K</td>
</tr>
<tr>
<td>EH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$16.00</td>
<td>$349.6K</td>
<td>1.7K</td>
<td>8.3K</td>
</tr>
</tbody>
</table>

<h3>About EHang Holdings</h3>
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
<h3>Where Is EHang Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 7,647,963, the EH's price is down by -11.91%, now at $13.46. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 113 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for EHang Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

EHang Holdings Unusual Options Activity

TD Cowen analyst Max Rakhlenko maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Buy and raises the price target from $165 to $195.

TD Cowen Maintains Buy on Williams-Sonoma, Raises Price Target to $195

Mizuho analyst Anthony Crowdell maintains AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) with a Outperform and lowers the price target from $24 to $16.

Mizuho Maintains Outperform on AES, Lowers Price Target to $16

On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental biologics license application for Andexxa (coagulation factor Xa (recombinant), inactivated -zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening <a href="https://www.benzinga.com/general/health-care">or uncontrolled bleeding.</a>
The FDA initially granted accelerated approval of <a href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-november-21-2024-meeting-announcement-11212024">Andexxa</a>, a recombinant modified human factor Xa (FXa) protein, in 2018 based on the change from baseline in anti-activated FXa (anti-FXa) activity, as a surrogate endpoint reasonably likely to predict clinical benefit as provided for in 21 CFR 601.41.
AstraZeneca was required to conduct a randomized controlled trial to verify and describe the clinical benefit of Andexxa, due to uncertainty as to the relation of the surrogate endpoint to clinical benefit and the observed clinical benefit to ultimate outcomes in the indicated population. In January 2024, the company submitted a supplemental Biologics Licensing Application for Andexxa with the results of the ANNEXA-I trial to fulfill this requirement.
Before the meeting, the FDA panel released <a target="_blank" href="https://www.fda.gov/media/183674/download" rel="noreferrer noopener">brief</a> documents highlighting some safety issues and other concerns.
"Although andexanet showed superiority of the primary efficacy endpoint over UC [usual care] within the PEP [primary efficacy population], the superior efficacy at 12 hours did not predict longer-term benefit," FDA said.
The major safety findings included a doubling of the rate of thromboses and thrombosis-related deaths at Day 30 in the andexanet arm compared with UC.
The major topics for discussion:
<ul>
<li>ANNEXA-I demonstrated an increased incidence of thrombosis (14.6% versus 6.9%) and thrombosis-related deaths at Day 30 (2.5% versus 0.9%) in the andexanet arm compared with the UC arm, respectively. These findings raise concerns regarding whether the serious risks of treatment with andexanet are acceptable in the indicated population.</li>
<li>While the primary efficacy endpoint in ANNEXA-I was met, the treatment difference across arms appears to be primarily driven by one of three components of the composite endpoint, namely the volume of hematoma at 12 hours, while other clinically meaningful endpoints were not different between the two arms. These findings raise the question as to whether the benefit demonstrated in ANNEXA-I outweighs the serious risks.</li>
</ul>
The document highlighted, &#8220;Treatment with andexanet demonstrated a statistically significant improvement in hemostasis compared to UC (andexanet: 65.7% versus UC: 53%). The observed treatment difference between arms appears to be primarily driven by hematoma volume, with more patients in the andexanet arm than UC arm experiencing a ≤35% increase from baseline in hematoma volume at 12 hours (74% versus 60%).&#8221;
Hematoma is a blood collection that pools outside blood vessels, usually caused by an injury or surgery.
Price Action: AZN stock is up 0.97% at $63.82 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42110605/deere-q4-earnings-beats-expectations-steep-sales-drop-margins-squeeze-more" target="_blank" rel="noreferrer noopener">Deere Q4 Earnings: Beats Expectations, Steep Sales Drop, Margins Squeeze &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Biotech

Large Cap

Health Care

General

AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns

SWVL

Swvl Holdings shares are trading higher after the company announced it signed a three-year contract with G4S in Saudi Arabia to provide SaaS-based mobility solutions.

Mizuho analyst Vijay Rakesh maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and raises the price target from $165 to $175.

NVDA

Mizuho Maintains Outperform on NVIDIA, Raises Price Target to $175

<a href="https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer" title="https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer">https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer</a>

Legal

'Texas-Based Oil-and-Gas Company Phillips 66 Indicted for Alleged Violations of Clean Water Act Stemming from Wastewater Discharge' - CA Attorney

Reaffirms Revenue Recognition Impact of $4 to $6 million
Ending Cash Position of Approximately $56 Million as of September 30, 2024, Consistent with Internal Forecasts
Announces Remedial Actions and Organizational Changes, Including the Resignation of the Company's Chief Financial Officer
Hires Leading Business Advisory Firm, AlixPartners, to Provide Interim Finance and Accounting Resources
Evolv Technology ("Evolv" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced the results of the internal investigation previously disclosed on October 25, 2024, into certain sales practices that impacted revenue recognition and other metrics.

Earnings

Management

EVLV

Earlier Reported, Evolv Technology Announces The Results Of Its Internal Investigation; Reaffirms Revenue Recognition Impact Of $4M-$6M; Ending Cash Position Of ~$56M As Of September 30, 2024, Consistent With Internal Forecasts; Mark Donohue, The Company's CFO And Principal Financial Officer And Principal Accounting Officer, Has Resigned; Hires Leading Business Advisory Firm, AlixPartners, To Provide Interim Finance And Accounting Resources

FLYE

Fly-E Group shares are trading lower after the company reported a year-over-year decrease in Q2 financial results.

Kyndryl shares are trading higher after the company's board authorized a $300 million share repurchase program.

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) has expanded its collaboration with XPEL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEL#NASDAQ">XPEL</a>) to offer a new customization program for its R1T and R1S electric vehicle owners<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42096490/xpel-and-rivian-expand-collaboration-with-new-ppf-and-window-film-program" rel="noreferrer noopener"> in the U.S. and Canada.</a>
The program, available through Rivian&#8217;s Gear Shop, allows owners to order XPEL&#8217;s Paint Protection Film (PPF) and Window Film products directly, with set pricing and easy installation booking through a local XPEL Certified Rivian Network Partner.
Rivian owners can now protect their vehicles with XPEL&#8217;s ULTIMATE PLUS Paint Protection Film, which guards against scratches, chips, and stains while offering a self-healing finish. The film also resists UV yellowing to maintain clarity.
Additionally, the PRIME Window Film provides added privacy, heat rejection, and UV protection, blocking 99% of harmful UV rays. Owners can choose from various window film tints, including PRIME CS, XR, and XR PLUS.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42113449/natural-gas-prices-spike-to-over-1-year-highs-oil-surges-to-70-as-russia-fires-intercontinental-ballistic-missile-to-ukraine" rel="noreferrer noopener">Natural Gas Prices Spike To Over 1-Year Highs, Oil Surges To $70 As Ukraine Says Intercontinental Ballistic Missile Fired By Russia</a>
This collaboration builds on Rivian&#8217;s previous partnership with XPEL, where the company offered full-body PPF on select models at the factory. The extended program aims to give owners greater protection and customization options, enhancing their Rivian ownership experience.
To participate, U.S. and Canadian customers can order and schedule installation via Rivian&#8217;s Gear Shop or XPEL&#8217;s website.
Price Action: RIVN shares are trading higher by 0.40% to $10.09 at last check Thursday.
Photo by Tada Images on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111748/super-micro-computer-stock-is-rallying-thursday-whats-going-on" target="_blank" rel="noreferrer noopener">Super Micro Computer Stock Is Rallying Thursday: What&#8217;s Going On?</a></li>
</ul>

RIVN

XPEL

Rivian Automotive Expands Collaboration With XPEL: Details

CRGO

Freightos shares are trading higher after the company announced the official launch of its integration with e2open.

Shares of Target Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) recovered slightly in early trading on Thursday, after tanking on the company's <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42106249/target-says-shoppers-wait-for-deals-a-day-after-rival-walmart-credits-market-gains-to-wealthy-households-tgt-edges-up-marginally-in-thursday-premarket">third-quarter earnings miss</a>.
<ul>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d9ee7bf6000154d225/christopher-horvers">analyst Christopher Horvers</a> maintained a Neutral rating, while slashing the price target from $167 to $139.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58580bcbee7bf60001bcfa29/kate-mcshane">analyst Kate McShane</a> reiterated a Buy rating, while reducing the price target from $192 to $164.</li>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61d8398a2925770001ed33b1/alexia-dogani">analyst Alexia Morgan</a> reaffirmed a Neutral rating, while cutting the price target from $156 to $130.</li>
<li>KeyBanc Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">analyst Bradley Thomas</a> maintained a Sector Weight rating on the stock. </li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
JPMorgan: Target's third-quarter comps of 0.3% came significantly below the consensus of 1.4%, "as weather, continued weakness in discretionary categories, and some share loss continue to weigh on discretionary spend," Horvers said in a note. Markdowns and promotions represented "the lion's share" of the company's third-quarter gross margin miss and is "the big driver of the implied drop in 4Q gross margins," he added.
"We believe TGT continues to face share issues of varying degrees across all categories, sans beauty, but the trend appears to be improving," the analyst wrote. The stock got battered after the earnings release and is likely to bounce bank, he further stated.
Goldman Sachs: Target's disappointing comps were due to a decline in ticket size, with consumers continuing to spend cautiously, "most notably in discretionary categories," McShane said. The company's beauty segment bucked the trend and delivered comps of more than 6%, while food &amp; beverage and essentials delivered low single-digit growth, she added.
Target's gross margin contracted by around 20 basis points to 27.2% and came in below consensus, the analyst stated. "We would note this was the most significant change for the quarter as 2Q gross margins were up ~190 bps," she further wrote.
Piper Sandler: "While part of the Q3 miss can be attributed to transitory factors surrounding supply chain costs and discretionary sales weakness (apparel, home, etc.), results also suggest some ongoing share loss," Morgan wrote in a note. The company's gross margin came in at 27.2%, significantly short of consensus of 28.5%, she added.
Target's performance hinges on a recovery in discretionary consumer spending and, once this happens, the company's fundamentals are likely to improve, the analyst stated. "However, we now have increased concerns with tariff dynamics and how they could impact supply chain and sourcing costs in 2025 &#8211; particularly considering today&#8217;s margin miss was partly from navigating port strikes," she further wrote.
KeyBanc Capital Markets: Target's third-quarter results missed expectations due to "slower sales and unexpected margin pressure," Thomas said. Lower ticket sizes weighed on comps, which came well below expectations, he added.
Given the disappointing third-quarter performance and soft expectations for the fourth quarter, management lowered their 2024 guidance for comps and earnings below consensus, the analyst stated. "Looking ahead, we see consumer headwinds, competitive pressures, and moderating margin opportunities as potentially limiting upside for shares," he further wrote.
Price Action: Shares of Target had declined by 0.62% to $122.51 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42100904/target-plunges-21-while-williams-sonoma-soars-27-on-same-day">Target Plunges 21% While Williams-Sonoma Soars 27% On Same Day</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Reiteration

Trading Ideas

Target Posts Q3 Earnings Miss: Analysts Slash Forecasts On Market Share Loss, Margin Concerns

Bank of America Securities analyst Lorraine Hutchinson has reiterated their neutral stance on UAA stock, giving a Hold rating yesterday. Lorraine H...

Under Armour's Improved Margins Lead to EPS Forecast Raise, But Hold Rating Maintained Amid Valuation Concerns

Baird analyst Jonathan Komp raised the firm's price target on Under Armour (UAA) to $10 from $8 and keeps a Neutral rating on the shares. The firm ...

Under Armour price target raised to $10 from $8 at Baird

Wells Fargo raised the firm's price target on Under Armour (UAA) to $11 from $8 and keeps an Equal Weight rating on the shares following the compan...

Under Armour price target raised to $11 from $8 at Wells Fargo

UBS raised the firm's price target on Under Armour (UA) (UAA) to $16 from $12 and keeps a Buy rating on the shares. The firm believes the company's...

Under Armour price target raised to $16 from $12 at UBS

There's a lot to be optimistic about in the Consumer Cyclical sector as 3 analysts just weighed in on Krispy Kreme (DNUT – Research Report), Under ...

Analysts Offer Insights on Consumer Cyclical Companies: Krispy Kreme (DNUT), Under Armour (UAA) and Brilliant Earth Group (BRLT)

Telsey Advisory analyst Cristina Fernandez raised the firm's price target on Under Armour (UAA) to $10 from $8 and keeps a Market Perform rating on...

Under Armour price target raised to $10 from $8 at Telsey Advisory

Under Armour ($UAA) has seen a surge in shares following better-than-expected earnings for Q2 and a revised outlook for its 2025 financial year. De...

Under Armour (UAA) Engineers a Turnaround, But Profits Continue to Decline

In a report released on November 8, Adrienne Yih from Barclays maintained a Hold rating on Under Armour (UAA – Research Report), with a price targe...

Barclays Remains a Hold on Under Armour (UAA)

Barclays raised the firm's price target on Under Armour (UA) (UAA) to $12 from $8 and keeps an Equal Weight rating on the shares. The company repor...

Under Armour price target raised to $12 from $8 at Barclays

Bearish flow noted in Under Armour (UAA) Class A with 15,299 puts trading, or 17x expected. Most active are Jan-25 7.5 puts and 11/22 weekly 9.5 ca...

Comments

Under Armour

Intérêt court

Under Armour (NYSE:UAA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL